Orchestra BioMed Holdings, Inc. (OBIO) Income Statement
OBIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOBIO revenue and net income
Where OBIO's revenue goes
2025Each bar shows an amount and its share of revenue. OBIO kept −157.4% of revenue as net income.
OBIO profit margins
OBIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1,169.2% | +111.6% | +42.5% | — |
| Gross profit | +1,267.8% | +118.1% | +43.0% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OBIO quarterly EPS vs estimates
Orchestra BioMed beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.40).
OBIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M | $0 | $5.7M |
| Cost of revenue | $190,000 | $204,000 | $186,000 | $322,000 | $199,000 | $145,000 |
| Gross profit | $33.3M | $2.4M | $2.6M | $3.2M | −$981,000 | $5.6M |
| Research & development | $58.2M | $42.8M | $33.8M | $21.9M | $12.9M | $13.5M |
| Sales, general & admin | $26.9M | $23.9M | $20.3M | $14.0M | $7.9M | $10.8M |
| Total operating expenses | $85.1M | $66.7M | $54.1M | $35.9M | $20.8M | $24.3M |
| Operating income | −$51.8M | −$64.3M | −$51.5M | −$32.7M | −$21.8M | −$18.8M |
| Interest income | — | $3.4M | $3.8M | $50,000 | — | $331,000 |
| Interest expense | $1.1M | — | — | — | $927,000 | — |
| Income before taxes | −$52.7M | −$61.0M | −$49.1M | −$33.6M | −$23.0M | −$21.4M |
| Income taxes | — | — | $119,105 | −$222,000 | $927,000 | $2.6M |
| Net income | −$52.7M | −$61.0M | −$49.1M | −$33.6M | −$23.0M | −$21.4M |
| EBITDA | −$51.2M | −$60.7M | −$48.8M | −$33.4M | −$21.9M | −$18.6M |
| EPS (diluted) | −$1.13 | −$1.66 | −$1.50 | −$0.19 | −$0.02 | −$0.01 |
| Gross margin | 99.4% | 92.3% | 93.3% | 90.9% | — | 97.5% |
| Operating margin | −154.7% | −2,437.5% | −1,866.2% | −924.3% | — | −328.8% |
| Net margin | −157.4% | −2,313.3% | −1,779.7% | −951.3% | — | −374.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88,000 | $110,000 | $30.9M | $861,000 | $836,000 | $868,000 | $253,000 | $987,000 | $778,000 | $620,000 | $262,000 | $419,000 |
| Cost of revenue | $25,000 | $92,000 | $51,000 | $49,000 | $46,000 | $44,000 | $58,000 | $68,000 | $44,000 | $108,000 | $83,000 | $41,000 |
| Gross profit | $63,000 | $18,000 | $30.9M | $812,000 | $790,000 | $824,000 | $195,000 | $919,000 | $734,000 | $512,000 | $179,000 | $378,000 |
| Research & development | $16.6M | $15.8M | $16.8M | $14.0M | $13.9M | $13.5M | $11.0M | $11.6M | $11.1M | $9.1M | $8.5M | $8.6M |
| Sales, general & admin | $5.8M | $6.4M | $7.3M | $7.1M | $6.3M | $6.3M | $5.9M | $5.7M | $6.5M | $5.9M | $4.2M | $6.3M |
| Total operating expenses | $22.4M | $22.1M | $24.1M | $21.1M | $20.1M | $19.7M | $16.9M | $17.3M | $17.6M | $14.9M | $12.7M | $14.9M |
| Operating income | −$22.4M | −$22.1M | $6.8M | −$20.3M | −$19.3M | −$18.9M | −$16.7M | −$16.3M | −$16.9M | −$14.4M | −$12.5M | −$14.5M |
| Interest income | — | — | — | — | — | $166,000 | $522,000 | $916,000 | $902,000 | $1.0M | — | $915,000 |
| Interest expense | $1.8M | $821,000 | $763,000 | $515,000 | $36,000 | — | — | — | — | — | $351,000 | — |
| Income before taxes | −$23.8M | −$20.7M | $6.2M | −$20.8M | −$19.4M | −$18.8M | −$16.2M | −$15.4M | −$16.0M | −$13.5M | −$12.8M | −$13.3M |
| Income taxes | — | — | — | — | — | — | −$30,724 | — | — | $30,724 | $2.7M | −$1.2M |
| Net income | −$23.8M | −$20.7M | $6.2M | −$20.8M | −$19.4M | −$18.8M | −$16.2M | −$15.4M | −$16.0M | −$13.5M | −$12.8M | −$13.3M |
| EBITDA | −$23.7M | −$19.8M | $7.1M | −$20.7M | −$19.3M | −$18.7M | −$16.1M | −$15.3M | −$15.9M | −$13.4M | −$12.7M | −$13.2M |
| EPS (diluted) | −$0.38 | −$0.33 | $0.26 | −$0.40 | −$0.50 | −$0.49 | −$0.42 | −$0.41 | −$0.45 | −$0.38 | −$0.37 | −$0.38 |
| Gross margin | 71.6% | 16.4% | 99.8% | 94.3% | 94.5% | 94.9% | 77.1% | 93.1% | 94.3% | 82.6% | 68.3% | 90.2% |
| Operating margin | −25,404.5% | −20,069.1% | 21.8% | −2,359.2% | −2,311.8% | −2,179.8% | −6,591.7% | −1,655.7% | −2,167.0% | −2,326.3% | −4,763.7% | −3,466.3% |
| Net margin | −26,994.3% | −18,810.0% | 20.2% | −2,419.0% | −2,316.1% | −2,160.7% | −6,385.4% | −1,562.9% | −2,054.0% | −2,171.5% | −4,892.4% | −3,178.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OBIO's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OBIO financial results
In fiscal year 2025 (ended December 31, 2025), Orchestra BioMed reported revenue of $33.5 million, up 1,169.2% from the year before. It had a net loss of $52.7 million, a net profit margin of −157.4%. Diluted earnings per share came to −$1.13. Over five years revenue grew at an average rate of 42.5% a year.
See the OBIO stock overview for the latest quote and news, or the OBIO chart for price history and technical indicators.
OBIO income statement FAQ
What is Orchestra BioMed's annual revenue?
Orchestra BioMed reported total revenue of $33.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 1,169.2% from $2.6 million the previous year.
Is Orchestra BioMed profitable?
No. Orchestra BioMed reported a net loss of $52.7 million in fiscal 2025, a net profit margin of −157.4%; its operating margin was −154.7%.
What is Orchestra BioMed's gross margin?
Orchestra BioMed's gross margin was 99.4% in fiscal 2025: for every $100 of revenue, Orchestra BioMed kept $99 after the direct cost of its products and services.
How much does Orchestra BioMed spend on research and development?
Orchestra BioMed spent $58.2 million on research and development in fiscal 2025, 173.8% of revenue.
How fast is Orchestra BioMed growing?
Revenue grew 42.5% a year on average over the last five fiscal years, from $5.7 million to $33.5 million.
What are Orchestra BioMed's earnings per share?
Orchestra BioMed earned $-1.13 per diluted share in fiscal 2025, compared with $-1.66 a year earlier.
When will Orchestra BioMed report its next earnings?
Orchestra BioMed is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Orchestra BioMed's fiscal year end?
Orchestra BioMed's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.